BioSpace News Archive

iSpecimen Inc. today announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.

Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received regulatory approval by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic Injection.

vTv Therapeutics Inc. is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.

Jaguar Health, Inc. (NASDAQ:JAGX) today provided a corporate update and outlined expected 2022 milestones.

Biofrontera Inc. today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021.

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.

Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents.

Mentor Worldwide LLC, the number one global brand in breast aesthetics, and part of the Johnson & Johnson Medical Devices Companies** today announced that the U.S. Food and Drug Administration (FDA) approved the MENTOR® MemoryGel BOOST™ Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company’s 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates with high-quality, real-world opportunities at work.

Halberd, Inc., an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, announces that they have been able to successfully eliminate Beta Amyloid and Interleukin-4 from synthetic cerebral spinal fluid in its latest in-vitro laboratory testing.